NCT01235416已完成1 期
A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 57
- 主要终点
- incidence of dose-limiting toxicities
研究概览
简要总结
This study is an open-label, dose-finding study to determine the target or maximum-tolerated dose and to characterize the safety and pharmacokinetic profile of AMG 706 administered in combination with erlotinib with or without gemcitabine in subjects with solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically or cytologically documented solid tumors
- •candidates for gemcitabine and erlotinib treatment (for cohorts with gemcitabine), in the opinion of the investigator
- •candidates for erlotinib treatment (for cohorts without gemcitabine), in the opinion of the investigator
- •Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2 (see Appendix E)
- •systolic blood pressure ≤ 145 mm Hg and diastolic blood pressure ≤ 85 mm Hg (hypertension therapy is allowed)
- •at least 18 years of age when written informed consent is obtained
- •before any study-specific procedure is performed, the appropriate approved written informed consent must be obtained (Section 12.1).
排除标准
- •nonsmall-cell lung cancer with squamous-cell histology
- •large central tumor lesions (ie, ≥ 3 centimeters and located adjacent to or within the hilum or mediastinum)
- •direct bowel wall invasion except for primary tumors of the bowel
- •evidence of active bleeding or bleeding diathesis
- •total gastrectomy
- •hematologic malignancies
- •untreated or symptomatic brain metastases
- •history or evidence of interstitial lung disease
- •past or current history of second neoplasm, except for curatively treated non-melanoma skin cancer, carcinoma in situ of the cervix and other primary solid cancer with no known active disease present and no curative treatment administered for the last 3 years
- •documented myocardial infarction within 1 year before study day 1
- •arterial thrombosis or deep vein thrombosis within 1 year before study day 1
- •unstable or uncontrolled disease/condition related to or impacting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association (NYHA) > class II [Appendix F])
- •major surgical procedure within 30 days before study day 1
- •known positive test for human immunodeficiency virus (HIV)
- •absolute neutrophil count (ANC) < 1.5 x 109 /L
- •platelet count < 100 x 109 /L or > 850 x 109 /L
- •hemoglobin < 9 g/dL
- •serum creatinine > 2.0 mg/dL or calculated clearance < 40 mL/minute
- •albumin-adjusted serum calcium < 2.0 mmol/L (8.0 mg/dL)
- •urine protein quantitative value of ≥ 30 mg/dL in urinalysis or ≥ 1+ on dipstick, unless 24-hour urine protein is < 500 mg
- •aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN) or AST or ALT > 5.0 x ULN if the subject has documented liver metastasis or primary hepatic neoplasm
- •total bilirubin > 2 x ULN (> 3 x ULN for subjects with Gilbert syndrome. Subjects with UGT1A1 promoter polymorphism, i.e. Gilbert syndrome, must be confirmed by genotyping or Invader® UGT1A1 Molecular Assay)
- •prothrombin time > 2.0 international normalized ratio or partial thromboplastin time > 1.5 X ULN
- •currently or previously treated with bevacizumab or small molecular inhibitors of VEGF including but not limited to SU11248 (sunitinib malate), PTK787 (vatalanib), AZD 2171, AEE-788, BAY 43- 9006 (sorafenib tosylate) and AMG 706, unless approved by Amgen
- •previously treated with erlotinib
- •previously treated with gemcitabine (for cohorts with gemcitabine) unless approved by Amgen
- •currently treated with interferon
- •systemic chemotherapy within 21 days before study day 1
- •radiation therapy within 14 days before study day 1
- •concurrent or prior treatment with rifampin, rifabutin, rifapentin, phenytoin, carbamazepine, or phenobarbital within 14 days before study day 1
- •treatment with strong CYP 3A inhibitors or inducers (such as but not limited to ketoconazole, itraconazole, clarithromycin, erythromycin or nefazodone) or immune modulators (such as but not limited to cyclosporine and tacrolimus) 7 days before study day 1
- •treatment with herbal medications containing St John's Wort within 7 days before study day 1
- •treatment for systemic infection within 14 days before study day 1
- •treated with > 1 mg/day of warfarin within 7 days before study day 1
- •any condition which in the investigator's opinion makes the subject unsuitable for study participation
- •not yet completed at least 30 days since ending other investigational device/drug trial(s), or subject is receiving other investigational treatments
- •pregnant (ie, positive beta-human chorionic gonadotropin test) or is breast feeding
- •not using adequate contraceptive precautions
- •unable to swallow oral medications
- •previously enrolled into this study
- •not available for follow-up assessments
研究组 & 干预措施
AMG 706 50mg
Active Comparator
50 mg, once daily. (Cohort 1)
干预措施: AMG 706 (Drug)
AMG 706 75mg
Active Comparator
75 mg, twice daily. (Cohort 2)
干预措施: AMG 706 (Drug)
AMG 706 125mg
Active Comparator
125 mg, once daily. (Cohort 3)
干预措施: AMG 706 (Drug)
结局指标
主要结局
incidence of dose-limiting toxicities
时间窗: Subjects will be in this study for up to 54 weeks (ie, 2 weeks screening, 48 weeks treatment and 4 weeks follow-up) or longer if subjects are deemed to have continuous clinical benefit from the combination chemotherapy and AMG 706
次要结局
- Incidence of adverse events (including serious and treatment-related) and significant laboratory values other than those defined as dose-limiting toxicities(Subjects will be in this study for up to 54 weeks (ie, 2 weeks screening, 48 weeks treatment and 4 weeks follow-up) or longer if subjects are deemed to have continuous clinical benefit from the combination chemotherapy and AMG 706)
- pharmacokinetic profiles of erlotinib and AMG 706(Subjects will be in this study for up to 54 weeks (ie, 2 weeks screening, 48 weeks treatment and 4 weeks follow-up) or longer if subjects are deemed to have continuous clinical benefit from the combination chemotherapy and AMG 706)
研究者
相似试验
已完成
1 期
A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid TumorsCancerNCT00268905Eisai Inc.64
已完成
1 期
Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid TumorsPatients With Advanced or Metastatic Solid TumorsNCT02867397Disphar International B.V.25
已完成
1 期
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or OlderAcute Myelogenous LeukemiaNCT01814826Millennium Pharmaceuticals, Inc.64
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsLung CancerLung CancerBreast CancerNCT06618287Bristol-Myers Squibb416
终止
1 期
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT01464034Criterium, Inc.136